COVID-19相关心脏非闭塞性纤维蛋白微血栓的病理研究
该研究对COVID-19(15例,其中12例活动期、3例已清除)、流感A/B(6例)及非病毒性死亡(6例)病例进行心脏尸检评估。结果显示活动性COVID-19组非闭塞性纤维蛋白微血栓更常见(P=0.006),心肌炎见于33.3%的COVID-19病例但通常局限,未发现直接心肌感染的明确证据。
要点
- 活动性COVID-19患者心脏非闭塞性纤维蛋白微血栓更常见(P=0.006)。
- 心肌炎见于33.3%的活动性和已清除COVID-19病例,但通常局限。
- 未发现SARS-CoV-2直接感染心肌的明确证据。
核心结论
- 心脏组织病理、免疫组化、超微结构和分子检测未显示直接心肌感染的明确证据。
- COVID-19病例常见心脏纤维蛋白微血栓,但并非普遍伴有急性缺血性损伤。
- 心肌炎见于33.3%的活动性和已清除COVID-19患者,但通常范围局限。
研究设计与样本
- 研究病例来自机构档案,包括COVID-19(n=15:12例活动性,3例已清除)、流感A/B(n=6)和非病毒性死亡(n=6)。
- 采用光镜检查、血管紧张素转换酶2免疫组化H评分比较,以及SARS-CoV-2免疫组化、超微结构检查和微滴数字聚合酶链反应进行病毒检测。
主要发现
- 非闭塞性纤维蛋白微血栓(无缺血性损伤)见于16例(12例COVID-19、2例流感、2例对照),在活动性COVID-19队列中更常见(P=0.006)。
- 4例活动性COVID-19显示局灶性心肌炎,1例已清除COVID-19显示广泛病变。
- COVID-19病例小动脉内皮血管紧张素转换酶2表达低于对照组(P=0.004)。
- 心肌血管紧张素转换酶2表达在疾病类别、性别、年龄或患者合并症数量间无差异(分别为P=0.69、P=1.00、P=0.46、P=0.65)。
- SARS-CoV-2免疫组化显示非特异性染色,超微结构检查和微滴数字聚合酶链反应病毒检测阴性。
关键数值与推荐
- 非闭塞性纤维蛋白微血栓在活动性COVID-19组更常见(P=0.006)。
- 心肌炎存在于33.3%的活动性和已清除COVID-19患者。
- 小动脉内皮血管紧张素转换酶2表达在COVID-19病例低于对照组(P=0.004)。
- 4例(26.7%)COVID-19患者有心脏淀粉样变性。
临床怎么用
- COVID-19患者心脏可见纤维蛋白微血栓,但未必导致急性缺血性损伤。
- 心肌炎在COVID-19中通常局限,需结合临床评估。
- 心脏淀粉样变性可能是重症COVID-19的额外风险因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its resultant clinical presentation, coronavirus disease 2019 (COVID-19), is an emergent cause of mortality worldwide. Cardiac complications secondary to this infection are common; however, the underlying mechanisms of such remain unclear. A detailed cardiac evaluation of a series of individuals with COVID-19 undergoing postmortem evaluation is provided, with 4 aims: (1) describe the pathological spectrum of the myocardium; (2) compare with an alternate viral illness; (3) investigate angiotensin-converting enzyme 2 expression; and (4) provide the first description of the cardiac findings in patients with cleared infection. METHODS: Study cases were identified from institutional files and included COVID-19 (n=15: 12 active, 3 cleared), influenza A/B (n=6), and nonvirally mediated deaths (n=6). Salient information was abstracted from the medical record. Light microscopic findings were recorded. An angiotensin-converting enzyme 2 immunohistochemical H-score was compared across cases. Viral detection encompassed SARS-CoV-2 immunohistochemistry, ultrastructural examination, and droplet digital polymerase chain reaction. RESULTS: Male sex was more common in the COVID-19 group (P=0.05). Nonocclusive fibrin microthrombi (without ischemic injury) were identified in 16 cases (12 COVID-19, 2 influenza, and 2 controls) and were more common in the active COVID-19 cohort (P=0.006). Four active COVID-19 cases showed focal myocarditis, whereas 1 case of cleared COVID-19 showed extensive disease. Arteriolar angiotensin-converting enzyme 2 endothelial expression was lower in COVID-19 cases than in controls (P=0.004). Angiotensin-converting enzyme 2 myocardial expression did not differ by disease category, sex, age, or number of patient comorbidities (P=0.69, P=1.00, P=0.46, P=0.65, respectively). SARS-CoV-2 immunohistochemistry showed nonspecific staining, whereas ultrastructural examination and droplet digital polymerase chain reaction were negative for viral presence. Four patients (26.7%) with COVID-19 had underlying cardiac amyloidosis. Cases with cleared infection had variable presentations. CONCLUSIONS: This detailed histopathologic, immunohistochemical, ultrastructural, and molecular cardiac series showed no definitive evidence of direct myocardial infection. COVID-19 cases frequently have cardiac fibrin microthrombi, without universal acute ischemic injury. Moreover, myocarditis is present in 33.3% of patients with active and cleared COVID-19 but is usually limited in extent. Histological features of resolved infection are variable. Cardiac amyloidosis may be an additional risk factor for severe disease.
引用
- Bois MC, Boire NA, Layman AJ, et al. COVID-19-Associated Nonocclusive Fibrin Microthrombi in the Heart. Circulation. 2020. PMID: 33197204. doi:10.1161/CIRCULATIONAHA.120.050754
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。